General Archive

-
News releasesFrom donkeys to diversity – Anji Miller reports from AUTM 2023
Takeaways from AUTM’s Annual Conference for the technology transfer sector
-
News releases
£3m fund to accelerate development of new CF therapies
Collaborative funding to drug discovery innovators to accelerate new treatments for people with cystic fibrosis.
-
News releasesLifeArc responds to the Government’s Spring Budget
LifeArc CEO Dr Melanie Lee responds to today’s Spring Budget.
-
ArticlesInternational Women’s Day 2023
Tips on career advancement, from some of LifeArc’s incredible women
-
News releasesThe Aisling Burnand Daphne Jackson Research Fellowship, sponsored by LifeArc
The Board at LifeArc announces today it is sponsoring five Daphne Jackson Fellowships.
-
ArticlesHonouring the contribution of a remarkable trustee – Aisling Burnand CBE
Melanie Lee pays tribute to Aisling Burnand and her immense contribution to the life sciences sector.
-
ArticlesRare Disease Day 2023 – Robbie’s story
Robbie has a rare genetic neurodegenerative disease known as AP-4 Hereditary Spastic Paraplegia (AP-4 HSP) subtype SPG47.
-
ArticlesFour ways we support rare disease research
LifeArc provides a range of advice, funding and science to help scientists turn promising research into potential treatments.
-
ArticlesLifeArc awards £3 million to advance promising early rare disease research from the lab to the patient
Pump-prime funding to help researchers get innovative approaches off the ground
-
News releasesLifeArc Ventures invests in Maxion Therapeutics
Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
-
ArticlesCelebrating the International Day of Women and Girls in Science
LifeArc celebrates this year’s UN Day for Women and Girls in STEM.
-
News releasesLifeArc Ventures – strong performance in 2022 & sustained investment in innovation
LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, provides an update on its portfolio.
